Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | PRKCA | P17252 | 4/20 | 0.56 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.51 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.51 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.51 |
| ▸ | LPAR3 | Q9UBY5 | 7/20 | 0.49 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.49 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2401659 | 0.96 | PRKCA (0.59) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL24704010 | 0.96 | ALDH1A1 (0.64) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| Tributyrin SCHEMBL14976537 | 0.94 | ALDH1A1 (0.54) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL3193751 | 0.93 | ALDH1A1 (0.58) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL1097712 | 0.90 | ALDH1A1 (0.56) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| Triacetin SCHEMBL21828461 | 0.90 | PRKCA (0.53) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| Tributyrin SCHEMBL601928 | 0.89 | ALDH1A1 (0.72) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| Tributyrin SCHEMBL23825 | 0.89 | ALDH1A1 (0.72) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL23219297 | 0.89 | LPAR3 (0.58) | ALDH1A1LMNAPRKCALPAR3LPAR1 | |
| SCHEMBL13208745 | 0.88 | PRKCA (0.58) | ALDH1A1LMNAPRKCAPRKCEPRKCQ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11918550-B2 | Sensitization of cancer cells to differentiation therapy with mitochondrial uncoupler niclosamide ethanolamine | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-03-05 | — | — | US | disclosed |
| US-11684601-B2 | Treatment of cancer with combinations of agents | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-06-27 | — | — | US | disclosed |
| US-20220175704-A1 | SENSITIZATION OF CANCER CELLS TO DIFFERENTIATION THERAPY WITH MITOCHONDRIAL UNCOUPLER NICLOSAMIDE ETHANOLAMINE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2022-06-09 | — | — | US | disclosed |
| US-10765654-B2 | Methods and compounds for treating cancer | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2020-09-08 | — | — | US | disclosed |
| US-20200261393-A1 | TREATMENT OF CANCER WITH COMBINATIONS OF AGENTS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2020-08-20 | — | — | US | disclosed |
| US-20140142152-A1 | METHODS AND COMPOUNDS FOR TREATING CANCER | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2014-05-22 | — | — | US | disclosed |
| WO-2013013061-A1 | METHODS AND COMPOUNDS FOR TREATING CANCER | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2013-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220175704-A1 | SENSITIZATION OF CANCER CELLS TO DIFFERENTIATION THERAPY WITH MITOCHONDRIAL UNCOUPLER NICLOSAMIDE ETHANOLAMINE | RARS2, NME4, ALDH2 | ALDH1A1 206/4885LMNA 3685/4885PRKCA 2494/4885 |
| US-20140142152-A1 | METHODS AND COMPOUNDS FOR TREATING CANCER | UGCG, LPCAT1, MGMT | ALDH1A1 400/4885LMNA 796/4885PRKCA 2985/4885 |
| US-10765654-B2 | Methods and compounds for treating cancer | UGCG, LPCAT1, MGMT | ALDH1A1 400/4885LMNA 796/4885PRKCA 2985/4885 |
| US-11918550-B2 | Sensitization of cancer cells to differentiation therapy with mitochondrial uncoupler niclosamide ethanolamine | RARS2, NME4, ALDH2 | ALDH1A1 206/4885LMNA 3685/4885PRKCA 2494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.